In this issue of Dermatology Times, we continue to highlight the ways in which the COVID-19 pandemic is affecting your practice, while also noting important research and updates to clinical care. Read more stories from this issue here.
 
Dermatology Times cover
Practicing dermatology in the time of COVID-19
Read one New York dermatologist’s insights on practice survival and patient care during the pandemic.

The future of actinic keratosis treatment
It is estimated that 0.025% to 16% of all actinic keratosis (AK) lesions may progress into invasive SCC per year, and there is still no marker to predict which lesions will progress, according to a recent paper that outlined diagnostic challenges as well as current and pipeline treatment approaches.
Molecular study highlights drug differences in AD
A recent meta-analysis confirms cyclosporine as the most effective atopic dermatitis (AD) treatment at the molecular level, although dupilumab achieves broad cutaneous changes beyond those expected with specific Th2 inhibition.
IL-23 antagonist demonstrates favorable long-term safety
The interleukin-23 antagonist guselkumab demonstrated greater efficacy compared with adalimumab and secukinumab at week 48 in controlled clinical trials investigating treatment of moderate-to-severe plaque psoriasis.

Connect with us on Twitter and Facebook for daily updates.